$64.99
0.02[0.03%]
At close: May 17
$64.99
0[0.00%]
PreMarket: 7:22PM EDT
Alpine Immune Sciences
(NASDAQ:ALPN)Alpine Immune Sciences Stock (NASDAQ:ALPN), Analyst Ratings, Price Targets, Predictions
Alpine Immune Sciences Inc has a consensus price target of $38.75, established from looking at the 35 latest analyst ratings. The last 3 analyst ratings were released from Wedbush, TD Cowen, and Leerink Partners on May 16, 2024, April 16, 2024, and April 12, 2024. With an average price target of $43.33 between Wedbush, TD Cowen, and Leerink Partners, there's an implied -33.32% downside for Alpine Immune Sciences Inc from these 3 analyst ratings.
Analyst Firms Making Recommendations1
Wedbush
TD Cowen
Leerink Partners
RBC Capital
Wolfe Research
1calculated from analyst ratings published within the last 3 years
Analyst Ratings for Alpine Immune Sciences
| Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
| 05/16/2024 | Buy Now | 0.02% | Wedbush | Robert Driscoll | → $65 | Reiterates | Neutral → Neutral | Get Alert |
| 04/16/2024 | Buy Now | — | TD Cowen | Boris Peaker | — | Downgrade | Buy → Hold | Get Alert |
| 04/12/2024 | Buy Now | 0.02% | Leerink Partners | Thomas Smith | $42 → $65 | Downgrade | Outperform → Market Perform | Get Alert |
| 04/11/2024 | Buy Now | 0.02% | RBC Capital | Gregory Renza | $41 → $65 | Downgrade | Outperform → Sector Perform | Get Alert |
| 04/11/2024 | Buy Now | — | Wedbush | Robert Driscoll | — | Downgrade | Outperform → Neutral | Get Alert |
| 04/11/2024 | Buy Now | — | Wolfe Research | Andy Chen | — | Downgrade | Outperform → Peer Perform | Get Alert |
| 04/11/2024 | Buy Now | 0.02% | Morgan Stanley | Michael Ulz | $47 → $65 | Downgrade | Overweight → Equal-Weight | Get Alert |
| 04/09/2024 | Buy Now | -15.37% | Guggenheim | Vamil Divan | → $55 | Initiates | → Buy | Get Alert |
| 03/21/2024 | Buy Now | -23.07% | HC Wainwright & Co. | Joseph Pantginis | $50 → $50 | Maintains | Buy | Get Alert |
| 03/19/2024 | Buy Now | -27.68% | Morgan Stanley | Michael Ulz | $30 → $47 | Maintains | Overweight | Get Alert |
| 03/19/2024 | Buy Now | -27.68% | Wedbush | Robert Driscoll | → $47 | Reiterates | Outperform → Outperform | Get Alert |
| 03/19/2024 | Buy Now | -32.3% | Oppenheimer | Matthew Biegler | $33 → $44 | Reiterates | Outperform → Outperform | Get Alert |
| 03/19/2024 | Buy Now | -23.07% | HC Wainwright & Co. | Joseph Pantginis | $32 → $50 | Maintains | Buy | Get Alert |
| 03/12/2024 | Buy Now | -36.91% | RBC Capital | Gregory Renza | $29 → $41 | Maintains | Outperform | Get Alert |
| 02/15/2024 | Buy Now | — | Wolfe Research | Andy Chen | — | Initiates | → Outperform | Get Alert |
| 01/26/2024 | Buy Now | -46.15% | Wedbush | Robert Driscoll | $26 → $35 | Maintains | Outperform | Get Alert |
| 12/22/2023 | Buy Now | -50.76% | HC Wainwright & Co. | Joseph Pantginis | $17 → $32 | Maintains | Buy | Get Alert |
| 11/15/2023 | Buy Now | -59.99% | Wedbush | Robert Driscoll | → $26 | Reiterates | Outperform → Outperform | Get Alert |
| 11/03/2023 | Buy Now | -66.15% | RBC Capital | Gregory Renza | $19 → $22 | Maintains | Outperform | Get Alert |
| 11/03/2023 | Buy Now | -59.99% | Wedbush | Robert Driscoll | $19 → $29 | Maintains | Outperform | Get Alert |
| 11/03/2023 | Buy Now | -53.84% | Morgan Stanley | Michael Ulz | $17 → $30 | Maintains | Overweight | Get Alert |
| 10/18/2023 | Buy Now | -72.3% | Berenberg | Andy Chen | → $18 | Initiates | → Buy | Get Alert |
| 10/05/2023 | Buy Now | -70.76% | RBC Capital | Gregory Renza | → $19 | Initiates | → Outperform | Get Alert |
| 09/13/2023 | Buy Now | -73.84% | HC Wainwright & Co. | Joseph Pantginis | → $17 | Reiterates | Buy → Buy | Get Alert |
| 09/11/2023 | Buy Now | -66.15% | Oppenheimer | Mark Breidenbach | $14 → $22 | Maintains | Outperform | Get Alert |
| 09/01/2023 | Buy Now | -70.76% | Wedbush | Robert Driscoll | → $19 | Reiterates | Outperform → Outperform | Get Alert |
| 08/31/2023 | Buy Now | -73.84% | HC Wainwright & Co. | Joseph Pantginis | → $17 | Reiterates | Buy → Buy | Get Alert |
| 08/15/2023 | Buy Now | -70.76% | Wedbush | Robert Driscoll | $17 → $19 | Maintains | Outperform | Get Alert |
| 08/15/2023 | Buy Now | -73.84% | HC Wainwright & Co. | Joseph Pantginis | $11 → $17 | Maintains | Buy | Get Alert |
| 06/26/2023 | Buy Now | -78.46% | Oppenheimer | Mark Breidenbach | → $14 | Assumes | → Outperform | Get Alert |
FAQ
What is the target price for Alpine Immune Sciences (ALPN)?
The latest price target for Alpine Immune Sciences (NASDAQ: ALPN) was reported by Wedbush on May 16, 2024. The analyst firm set a price target for $65.00 expecting ALPN to rise to within 12 months (a possible 0.02% upside). 30 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Alpine Immune Sciences (ALPN)?
The latest analyst rating for Alpine Immune Sciences (NASDAQ: ALPN) was provided by Wedbush, and Alpine Immune Sciences reiterated their neutral rating.
When was the last upgrade for Alpine Immune Sciences (ALPN)?
There is no last upgrade for Alpine Immune Sciences.
When was the last downgrade for Alpine Immune Sciences (ALPN)?
The last downgrade for Alpine Immune Sciences Inc happened on April 16, 2024 when TD Cowen changed their price target from N/A to N/A for Alpine Immune Sciences Inc.
When is the next analyst rating going to be posted or updated for Alpine Immune Sciences (ALPN)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Alpine Immune Sciences, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Alpine Immune Sciences was filed on May 16, 2024 so you should expect the next rating to be made available sometime around May 16, 2025.
Is the Analyst Rating Alpine Immune Sciences (ALPN) correct?
While ratings are subjective and will change, the latest Alpine Immune Sciences (ALPN) rating was a reiterated with a price target of $0.00 to $65.00. The current price Alpine Immune Sciences (ALPN) is trading at is $64.99, which is within the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.